Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide-mediated cellular delivery.

J J Schwartz1, S Zhang

  • 1Center for Biomedical Engineering 56-341, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139-4307, USA. jschwart@MIT.EDU

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimaterial actinic spatial control 3D and 4D printing.

Nature communications·2019
Same author

Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data.

Transplantation proceedings·2018
Same author

Micropollutants in urban stormwater: occurrence, concentrations, and atmospheric contributions for a wide range of contaminants in three French catchments.

Environmental science and pollution research international·2013
Same author

Scleroderma.

Pharmedical notes ...·2010
Same author

Diabetes mellitus.

Pharmedical notes ...·2010
Same author

The biochemorphology of nicotine; observations on the progressive degradation of the pyrrolidine ring.

The Journal of pharmacology and experimental therapeutics·2010
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Peptide-based delivery systems offer a novel way to deliver therapeutics like DNA and proteins into cells. These systems bypass the need for genetic modification, enabling targeted biochemical intervention.

Area of Science:

  • Molecular biology
  • Biochemistry
  • Drug delivery systems

Background:

  • Gene therapy faces challenges with safe and efficient delivery of genetic material.
  • Existing delivery methods often require altering the target cell's genome.

Purpose of the Study:

  • To introduce peptide-mediated molecular therapeutics as an alternative to current gene therapy delivery methods.
  • To highlight the potential of these systems for targeted intracellular delivery of various molecules.

Main Methods:

  • Utilizing engineered peptides (e.g., TAT, VP22) as delivery vehicles.
  • Demonstrating in vitro and in vivo cellular uptake of DNA, nucleic acids, small molecules, and proteins.

Main Results:

  • Peptide systems efficiently deliver diverse therapeutic payloads into cells.

Related Experiment Videos

  • These systems offer versatility in cargo loading and targeting capabilities.
  • Successful delivery was achieved without altering the host cell genome.

    • Conclusions:

    • Peptide-mediated delivery systems represent a promising advancement in therapeutic delivery.
    • They provide a non-genomic approach for targeted intervention within target cells.
    • These systems have the potential to overcome key limitations in current gene therapy.